OMAHA, Neb.--(BUSINESS WIRE)--Transgenomic, Inc. (OTCBB: TBIO) today reported financial results for the three months ended, March 31, 2012, and provided a business update. “We made progress in the first quarter validating and advancing several of our new high-value products, including the NuclearMitome Test, ICE COLD-PCR in circulating tumor cells and PGxPredict®:CLOPIDOGREL response panel,” said Craig Tuttle, President and Chief Executive Officer. “Our investment in these groundbreaking new products and technologies will fuel growth over the long term and keep Transgenomic at the forefront of the pharmacogenomics and molecular diagnostics industry. Most notably, we continue to build momentum in building awareness around our proprietary, two gene clopidogrel response panel, a test which represents a potential multi-billion dollar market opportunity.”
